OLGX News Alert

Osteologix Executive to Present at 6th Annual Partnerships in Clinical Trials Congress and Exhibition 2007
Thursday November 1, 4:20 pm ET

SAN FRANCISCO--(BUSINESS WIRE)--Osteologix Inc. (OTC BB: OLGX.OB), a specialty pharmaceutical company, today announced that Malene Weis M.SC.Pharm., Director of Clinical Development of Osteologix, will give a presentation entitled ?Challenges for Small Pharma in Setting up and Managing a Clinical Trial? during a Symposium regarding outsourcing challenges for small pharma and biotech at the 6th Annual Partnerships in Clinical Trials Congress and Exhibition 2007 on Monday, November 5, 2007 in Amsterdam RAI, The Netherlands. Following her presentation, Weis will participate as a panel member during the Discussion Session entitled ?Developing an Outsourcing Strategy that Keeps Pace with Your Company?s Growth?. Weis has worked with all stages of clinical development at both pharmaceutical companies and contract research organizations (CROs). She has held prime responsibility for the design and operational execution of numerous clinical trials within various therapeutic areas, including Osteologix?s latest Phase II STRONG Study of the company?s lead drug candidate for the treatment and prevention of osteoporosis, NB S101. The data for the STRONG Study will be released in the 4th quarter of 2007.

The NB S101 Program and the STRONG Study

Osteologix has conducted extensive preclinical and clinical drug research with its proprietary DABA, NB S101. The Phase II STRONG Study evaluating NB S101 is a randomized, double-blind, placebo-controlled, parallel-group dose response study in 289 postmenopausal women. The results will provide data on the effects of NB S101 on bone metabolism, bone mineral density, safety, tolerability and pharmacokinetics. The primary endpoint in the trial is the change in patients' bone resorption, as measured by the biochemical marker CTX-1. Data from this trial will be reported in the fourth quarter of 2007.

About NB S101NB

S101 is a novel dual acting bone agent, or DABA, the active component of which significantly improves bone density and reduces fracture risk. In preclinical studies, NB S101 has demonstrated significant beneficial effects by reducing bone resorption and increasing high quality strong bone formation and bone mineralization. This dual action on bone? a significant medical need? suggests that NB S101 could fundamentally change the treatment paradigm of patients with osteoporosis. Importantly, NB S101 helps to build bone in a manner similar to the body?s own metabolic processes by rebalancing bone metabolism in a way that favors strong bone development. Osteologix has a competitive intellectual property position. A key patent for NB S101 has been issued in EU providing protection out to 2024, with US patents published and currently pending.

About Osteoporosis

Osteoporosis is the most common bone disease in humans and, according to the National Osteoporosis Foundation (NOF), 10 million Americans are estimated to have the disease and almost 34 million more are estimated to have osteopenia or low bone mass, placing them at increased risk for osteoporosis. The most severe consequence of osteoporosis is skeletal fracture. Osteoporosis is responsible for more than 1.5 million fractures annually and direct expenditures for hip fractures are estimated to cost society more than $18 billion annually. According to NOF, one in two women and one in four men over age 50 can be expected to have an osteoporosis-related fracture at some time.

About Osteologix

Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. The Company?s vision is to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.

For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com